amifostine anhydrous has been researched along with metronidazole in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chapman, JD; Urtasun, RC | 1 |
| Chu, F; Hilaris, BS; Kim, JH; Nori, D | 1 |
| Krimker, VM; Vinskaia, NP; Vygodskaia, AL | 1 |
| Kehrberg, G; Moldenhauer, H; Rose, H; Saul, G; Wolf, G | 1 |
2 review(s) available for amifostine anhydrous and metronidazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Modification of the radiation effects for overcoming radiation-resistant hypoxic tumor tissue].
Topics: Amifostine; Animals; Central Nervous System Diseases; Dogs; Humans; Hyperthermia, Induced; In Vitro Techniques; Intestines; Lymphocytes; Metronidazole; Mice; Misonidazole; Neoplasms; Neoplasms, Experimental; Nerve Tissue; Nitro Compounds; Oxygen; Radiation Dosage; Radiation-Protective Agents; Radiation-Sensitizing Agents; Rats | 1983 |
1 trial(s) available for amifostine anhydrous and metronidazole
| Article | Year |
|---|---|
Radiosensitizers and protectors.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Metronidazole; Misonidazole; Neoplasms; Oxygen; Pyrimidines; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1984 |
4 other study(ies) available for amifostine anhydrous and metronidazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
The application in radiation therapy of substances which modify cellular radiation response.
Topics: Amifostine; Animals; Drug Evaluation; Drug Therapy, Combination; Humans; Metronidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen Consumption; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1977 |
[Quantitative evaluation of the effectiveness of radiomodifiers in local irradiation of the skin].
Topics: Amifostine; Animals; Female; Metronidazole; Mice; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiodermatitis | 1982 |